{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:17:55Z","timestamp":1786465075067,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["grant #2D43TW009771-06"],"award-info":[{"award-number":["grant #2D43TW009771-06"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-026-00893-2","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:13:01Z","timestamp":1780715581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda"],"prefix":"10.1186","volume":"23","author":[{"given":"Esther M.","family":"Nasuuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kalyesubula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chido Dziva","family":"Chikwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"9","key":"893_CR1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S2352-4642(20)30037-7","volume":"4","author":"LJ Frigati","year":"2020","unstructured":"Frigati LJ, et al. Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy. Lancet Child Adolesc Health. 2020;4(9):688\u201398.","journal-title":"Lancet Child Adolesc Health"},{"issue":"8","key":"893_CR2","doi-asserted-by":"publisher","first-page":"e25386","DOI":"10.1002\/jia2.25386","volume":"22","author":"LJ Frigati","year":"2019","unstructured":"Frigati LJ, et al. Multisystem impairment in South African adolescents with Perinatally acquired HIV on antiretroviral therapy (ART). J Int AIDS Soc. 2019;22(8):e25386.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"893_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.kint.2017.11.007","volume":"93","author":"CR Swanepoel","year":"2018","unstructured":"Swanepoel CR, et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018;93(3):545\u201359.","journal-title":"Kidney Int"},{"issue":"1","key":"893_CR4","doi-asserted-by":"publisher","first-page":"18596","DOI":"10.7448\/IAS.16.1.18596","volume":"16","author":"R Bhimma","year":"2013","unstructured":"Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal HIV-1 infection. J Int AIDS Soc. 2013;16(1):18596.","journal-title":"J Int AIDS Soc"},{"key":"893_CR5","volume-title":"Updated recommendations in first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV","author":"world Health Organization","year":"2018","unstructured":"world Health Organization. Updated recommendations in first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Netherlands: World Health Organisation; 2018."},{"key":"893_CR6","first-page":"88","volume-title":"Consolidated Guidelines For the Prevention and Treatment of HIV in Uganda","author":"Ministry of Health","year":"2022","unstructured":"Ministry of Health. Consolidated Guidelines For the Prevention and Treatment of HIV in Uganda. Ministry of Health: kampala; 2022. pp. 88\u201398."},{"issue":"4","key":"893_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s13318-016-0394-6","volume":"42","author":"D Cattaneo","year":"2017","unstructured":"Cattaneo D, Gervasoni C. Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. Eur J Drug Metab Pharmacokinet. 2017;42(4):559\u201372.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"893_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12882-024-03865-8","volume":"25","author":"EM Nasuuna","year":"2024","unstructured":"Nasuuna EM, et al. Comparison of the prevalence and associated factors of chronic kidney disease diagnosed by serum creatinine or cystatin C among young people living with HIV in Uganda. BMC Nephrol. 2024;25(1):422.","journal-title":"BMC Nephrol"},{"key":"893_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1651-2227.2006.tb02378.x","volume":"450","author":"WHO Multicentre Growth Reference Study Group","year":"2006","unstructured":"WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length\/height, weight and age. Acta Paediatr Suppl. 2006;450:76\u201385.","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"893_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1161\/HYPERTENSIONAHA.117.10050","volume":"70","author":"JT Flynn","year":"2017","unstructured":"Flynn JT, Falkner BE. New Clinical Practice Guideline for the Management of High Blood Pressure in Children and Adolescents. Hypertension. 2017;70(4):683\u20136.","journal-title":"Hypertension"},{"issue":"27","key":"893_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","volume":"385","author":"A Turkova","year":"2021","unstructured":"Turkova A, et al. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021;385(27):2531\u201343.","journal-title":"N Engl J Med"},{"issue":"11","key":"893_CR12","doi-asserted-by":"publisher","first-page":"e25970","DOI":"10.1002\/jia2.25970","volume":"25","author":"CL Townsend","year":"2022","unstructured":"Townsend CL, et al. Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review. J Int AIDS Soc. 2022;25(11):e25970.","journal-title":"J Int AIDS Soc"},{"issue":"10","key":"893_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/aid.2021.0140","volume":"38","author":"V Kouamou","year":"2022","unstructured":"Kouamou V, et al. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale. AIDS Res Hum Retroviruses. 2022;38(10):774\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"893_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/INF.0000000000002733","volume":"39","author":"A Diack","year":"2020","unstructured":"Diack A, et al. Progressive Decline of the Glomerular Filtration Rate in HIV-infected Children Treated With Tenofovir Disoproxil Fumarate-based Regimens in West and Central Africa. Pediatr Infect Dis J. 2020;39(8):737\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"893_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-019-0227-1","volume":"16","author":"TJ Mtisi","year":"2019","unstructured":"Mtisi TJ, et al. Tenofovir-associated kidney disease in Africans: a systematic review. AIDS Res therapy. 2019;16(1):12.","journal-title":"AIDS Res therapy"},{"issue":"2","key":"893_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4103\/jdmimsu.jdmimsu_390_24","volume":"20","author":"OB Odegbemi","year":"2025","unstructured":"Odegbemi OB, et al. Renal function and nephrotoxicity assessment in people living with HIV on Tenofovir, Lamivudine, and Dolutegravir therapy: A cross-sectional study in Nigeria. J Datta Meghe Inst Med Sci Univ. 2025;20(2):364\u201372.","journal-title":"J Datta Meghe Inst Med Sci Univ"},{"key":"893_CR17","doi-asserted-by":"publisher","DOI":"10.2174\/011570162X384022250910065252","author":"S Patamatamkul","year":"2025","unstructured":"Patamatamkul S, Kanogtorn S, Putcharoen O. A randomized controlled trial evaluating virologic and renal outcomes after switching from TDF\/FTC\/EFV to TDF\/3TC\/DTG (TLD) versus DTG+ 3TC in virologically suppressed Thai PWH\u2013a pilot study. Curr HIV Res. 2025. https:\/\/doi.org\/10.2174\/011570162X384022250910065252.","journal-title":"Curr HIV Res"},{"issue":"2","key":"893_CR18","doi-asserted-by":"publisher","first-page":"e0318068","DOI":"10.1371\/journal.pone.0318068","volume":"20","author":"TS Yazie","year":"2025","unstructured":"Yazie TS, et al. Chronic kidney disease among people living with HIV on TDF based regimen: a systematic review and meta-analysis. PLoS One. 2025;20(2):e0318068.","journal-title":"PLoS One"},{"key":"893_CR19","doi-asserted-by":"publisher","first-page":"101462","DOI":"10.1016\/j.cegh.2023.101462","volume":"25","author":"ES Asirvatham","year":"2024","unstructured":"Asirvatham ES, et al. A review of Tenofovir Disoproxil Fumarate associated nephrotoxicity among People Living with HIV: Burden, risk factors and solutions. Clin Epidemiol Global Health. 2024;25:101462.","journal-title":"Clin Epidemiol Global Health"},{"issue":"9","key":"893_CR20","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","volume":"33","author":"SK Gupta","year":"2019","unstructured":"Gupta SK, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. Aids. 2019;33(9):1455\u201365.","journal-title":"Aids"},{"issue":"2","key":"893_CR21","doi-asserted-by":"publisher","first-page":"e26037","DOI":"10.1002\/jia2.26037","volume":"26","author":"J O\u2019Rourke","year":"2023","unstructured":"O\u2019Rourke J, et al. Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review. J Int AIDS Soc. 2023;26(2):e26037.","journal-title":"J Int AIDS Soc"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00893-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:03:44Z","timestamp":1786457024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12981-026-00893-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00893-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9091584\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Uganda Virus Research Institute (UVRI) Research Ethics Committee (GC\/127\/946), the Uganda National Council of Science and Technology (HS2578ES), and the London School of Hygiene and Tropical Medicine (reference 28797) approved this study. All participants regardless of age provided informed consent\/assent after provision of age-appropriate study information. Participants\u2009>\u200918 years s provided a written informed consent. Children\u2009<\u200918 years provided written assent, and their caregivers provided a written informed consent. The studies were conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}